ADA 2018: CV Benefits of SGLT-2 Inhibitors

Slideshow

Three studies at ADA 2018 highlight the current track record of SGLT-2is in reducing CV-related morbidity and mortality.

Newsletter

Enhance your clinical practice with the Patient Care newsletter, offering the latest evidence-based guidelines, diagnostic insights, and treatment strategies for primary care physicians.

Subscribe Now!
Recent Videos
New Research Amplifies Impact of Social Determinants of Health on Cardiometabolic Measures Over Time
Related Content
GLP-1 RAs Prescribed for More Than One-Third of US Adults With Diabetes in Middle Age: NHIS Data Brief / image credit ©Sebastian Garcia/stock.adobe.com

GLP-1 RAs Prescribed for More Than One-Third of US Adults With Diabetes in Middle Age: NCHS Data Brief

Grace Halsey
August 18th 2025
Article
Obesity & Type 2 Diabetes: An Expert Discussion

Obesity & Type 2 Diabetes: An Expert Discussion

Sydney Jennings
August 18th 2025
Podcast
Excess Intake of Ultraprocessed Foods is Tied to Higher Cardiometabolic Risk, AHA Advisory Panel Says

Excess Intake of Ultraprocessed Foods is Tied to Higher Cardiometabolic Risk, AHA Advisory Panel Says

Sydney Jennings
August 18th 2025
Article
Episode 17: Kidney Outcomes with Tirzepatide in Type 2 Diabetes

Episode 17: Kidney Outcomes with Tirzepatide in Type 2 Diabetes

Sydney Jennings
August 18th 2025
Podcast
What is Driving Type 2 Diabetes in the US? / image credit ©Zsido/Shutterstock.com

What is Driving Type 2 Diabetes in the US?

Grace Halsey
August 18th 2025
Article
t New Guidelines Recommend Preconception Screening in Diabetes, Universal Testing for Primary Aldosteronism

New Guidelines Recommend Preconception Screening in Diabetes, Universal Testing for Primary Aldosteronism

Grace Halsey
August 18th 2025
Article
© 2025 MJH Life Sciences

All rights reserved.